GB0911042D0 - Treatment of tumorigenic cells in solid tumours - Google Patents
Treatment of tumorigenic cells in solid tumoursInfo
- Publication number
- GB0911042D0 GB0911042D0 GBGB0911042.0A GB0911042A GB0911042D0 GB 0911042 D0 GB0911042 D0 GB 0911042D0 GB 0911042 A GB0911042 A GB 0911042A GB 0911042 D0 GB0911042 D0 GB 0911042D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- solid tumours
- tumorigenic cells
- tumorigenic
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0911042.0A GB0911042D0 (en) | 2009-06-25 | 2009-06-25 | Treatment of tumorigenic cells in solid tumours |
EP10737760A EP2445500A1 (en) | 2009-06-25 | 2010-06-25 | Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors |
PCT/EP2010/004119 WO2010149394A1 (en) | 2009-06-25 | 2010-06-25 | Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0911042.0A GB0911042D0 (en) | 2009-06-25 | 2009-06-25 | Treatment of tumorigenic cells in solid tumours |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0911042D0 true GB0911042D0 (en) | 2009-08-12 |
Family
ID=41008276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0911042.0A Ceased GB0911042D0 (en) | 2009-06-25 | 2009-06-25 | Treatment of tumorigenic cells in solid tumours |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2445500A1 (en) |
GB (1) | GB0911042D0 (en) |
WO (1) | WO2010149394A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2016054574A1 (en) * | 2014-10-03 | 2016-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response |
WO2016130667A1 (en) | 2015-02-10 | 2016-08-18 | Ohio State Innovation Foundation | Chlamydia-activated b cell platforms and methods thereof |
JP7086000B2 (en) | 2015-11-10 | 2022-06-17 | オハイオ・ステート・イノヴェーション・ファウンデーション | Methods and compositions for accelerating humoral affinity |
CA3030779A1 (en) | 2016-07-13 | 2018-01-18 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016781A1 (en) * | 1998-09-18 | 2000-03-30 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
CN100584840C (en) | 2004-01-05 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | Substituted heterocyclic compounds and uses thereof |
-
2009
- 2009-06-25 GB GBGB0911042.0A patent/GB0911042D0/en not_active Ceased
-
2010
- 2010-06-25 EP EP10737760A patent/EP2445500A1/en not_active Withdrawn
- 2010-06-25 WO PCT/EP2010/004119 patent/WO2010149394A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2445500A1 (en) | 2012-05-02 |
WO2010149394A1 (en) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0911042D0 (en) | Treatment of tumorigenic cells in solid tumours | |
ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
IL218575A0 (en) | Treatment of cancer | |
SG10201802522SA (en) | Treatment of pluripotent cells | |
HK1175476A1 (en) | Cancer treatment | |
SG10201508495VA (en) | Combination treatment of cancer | |
ZA201208413B (en) | Skin treatment composition | |
ZA201307036B (en) | Treatment of solid tumours | |
HRP20170225T1 (en) | Phosphaplatins and their use for treatment of cancers | |
IL222958A0 (en) | Cancer treatment | |
EP2404592A4 (en) | Hair treatment composition | |
ZA201202213B (en) | Treatment of minerals | |
ZA201105125B (en) | Hair treatment composition | |
PL388252A1 (en) | Combination therapy of colorectal cancer | |
ZA201208568B (en) | Skin treatment composition | |
ZA201201116B (en) | Hair treatment composition | |
ZA201202657B (en) | Use of the sparc microenvironment signature in the treatment of cancer | |
GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
GB0916686D0 (en) | Treatment of cancer | |
EP2552443A4 (en) | Improved treatment of renal cell carcinoma | |
IL220241A0 (en) | Use of transferrin in treatment of beta-thalassemias | |
GB201002499D0 (en) | Treatment of tumours | |
GB0921757D0 (en) | Treatment of cancer | |
HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
GB201017356D0 (en) | Combination treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |